ICU Medical, Inc. (NASDAQ:ICUI) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.77 per share for the quarter. ICU Medical has set its FY17 guidance at $3.80-4.20 EPS.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.06). ICU Medical had a net margin of 6.10% and a return on equity of 7.56%. The business had revenue of $331.51 million for the quarter, compared to analyst estimates of $318.30 million. During the same period in the prior year, the business earned $1.15 earnings per share. The company’s revenue for the quarter was up 242.8% on a year-over-year basis. On average, analysts expect ICU Medical to post $-3.52 EPS for the current fiscal year and $4.9 EPS for the next fiscal year.

Shares of ICU Medical, Inc. (NASDAQ:ICUI) opened at 190.05 on Tuesday. The firm has a market capitalization of $3.77 billion, a PE ratio of 76.11 and a beta of 0.35. ICU Medical, Inc. has a 12-month low of $127.00 and a 12-month high of $195.20. The company’s 50-day moving average price is $186.73 and its 200-day moving average price is $171.80.

ICUI has been the subject of several recent analyst reports. Gabelli restated a “buy” rating on shares of ICU Medical in a research note on Friday, August 11th. Zacks Investment Research upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $193.00 target price for the company in a research note on Thursday, July 20th. BidaskClub upgraded ICU Medical from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Finally, KeyCorp initiated coverage on ICU Medical in a research note on Tuesday, October 17th. They set a “sector weight” rating for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. ICU Medical currently has a consensus rating of “Hold” and a consensus target price of $193.00.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at

In other news, Director Robert S. Swinney sold 3,400 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $173.98, for a total value of $591,532.00. Following the completion of the transaction, the director now directly owns 20,893 shares in the company, valued at approximately $3,634,964.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Vivek Jain sold 97,795 shares of the stock in a transaction on Friday, October 20th. The shares were sold at an average price of $190.00, for a total value of $18,581,050.00. Following the completion of the transaction, the chairman now owns 67,680 shares of the company’s stock, valued at $12,859,200. The disclosure for this sale can be found here. Insiders sold a total of 120,247 shares of company stock valued at $22,708,888 over the last quarter. 13.60% of the stock is owned by corporate insiders.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Earnings History for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with's FREE daily email newsletter.